EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan

Keiko Maruyama-Sakurai iD, Hisateru Tachimori iD, Eiko Saito, Shun Kohsaka, Yasumasa Segawa, Hiroaki Miyata, Ataru Igarashi

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Keiko Maruyama-Sakurai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Cost-Benefit Analysis, Diabetic Nephropathies, Quality-Adjusted Life Years. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mitsubishi Tanabe Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the cost‐effectiveness of diabetic nephropathy treatment with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in Japanese clinical practice, considering diabetes‐related complications. Materials and Methods A population‐based Monte Carlo simulation was used to estimate the cost‐effectiveness for people with diabetic nephropathy who initiated pharmacotherapy with an SGLT2 inhibitor plus conventional treatment or conventional treatment alone, based on quality‐adjusted life‐years (QALYs) and healthcare costs. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation study (CREDENCE) and the Japanese Society for Dialysis Research statistical survey were the primary sources of probability and mortality, while Japanese Health Insurance Claims Data were the cost source. The state transition model included diabetic nephropathy, hospitalization due to cardiovascular disease, dialysis, and death. One‐way and probabilistic sensitivity analyses were used to explore model uncertainty.

Results

Using the threshold of JPY 5 000 000 per QALY, SGLT2 inhibitor plus conventional treatment was more cost‐effective than conventional treatment alone, with an incremental cost‐effectiveness ratio of JPY 654 309 per QALY. Treating 100 000 people, SGLT2 inhibitor plus conventional treatment prevented 2234 deaths and reduced 5793 fewer heart failure cases, 3967 fewer myocardial infarctions and stroke events. Sensitivity analysis affirmed the robustness of these results for patients aged under 70 years.

Conclusions

The SGLT2 inhibitor treatment appeared to be cost‐effective for the overall population of our study and particularly for younger patients (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsCost-Benefit AnalysisDiabetic NephropathiesQuality-Adjusted Life YearsMonte Carlo MethodDiabetes Mellitus, Type 2HumansJapanFemaleMaleMiddle AgedAgedCanagliflozinHealth Care Costs

Stichwörter der Autor:innen

JapanSGLT2 inhibitorcost‐effectivenessdiabetic nephropathy

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCanagliflozin

Autor:innen und Institutionen

  • Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan.
  • Endowed Course for Health System Innovation, Keio University School of Medicine, Tokyo, Japan.
  • Sustainable Society Design Center, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
  • Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
  • Graduate School of Data Sciences, Yokohama City University, Yokohama, Japan.
  • Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Keiko Maruyama-Sakurai, Hisateru Tachimori

Förderung

  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Maruyama-Sakurai, K., Tachimori, H., Saito, E., Kohsaka, S., Segawa, Y., Miyata, H., & Igarashi, A. (2024). Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15832

Vancouver

Maruyama-Sakurai K, Tachimori H, Saito E, Kohsaka S, Segawa Y, Miyata H, et al. Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15832

BibTeX
@article{MaruyamaSakurai2024,
  author = {Maruyama-Sakurai, Keiko and Tachimori, Hisateru and Saito, Eiko and Kohsaka, Shun and Segawa, Yasumasa and Miyata, Hiroaki and Igarashi, Ataru},
  title = {Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15832}
}
Kostenlos starten →